DE2337134A1 - Verfahren zur herstellung eines grippeimpfstoffes - Google Patents
Verfahren zur herstellung eines grippeimpfstoffesInfo
- Publication number
- DE2337134A1 DE2337134A1 DE19732337134 DE2337134A DE2337134A1 DE 2337134 A1 DE2337134 A1 DE 2337134A1 DE 19732337134 DE19732337134 DE 19732337134 DE 2337134 A DE2337134 A DE 2337134A DE 2337134 A1 DE2337134 A1 DE 2337134A1
- Authority
- DE
- Germany
- Prior art keywords
- strain
- mutants
- strains
- cultures
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 title description 2
- 241000700605 Viruses Species 0.000 claims description 91
- 210000002966 serum Anatomy 0.000 claims description 73
- 229960005486 vaccine Drugs 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 45
- 238000012360 testing method Methods 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 238000011161 development Methods 0.000 claims description 20
- 230000000890 antigenic effect Effects 0.000 claims description 16
- 230000002458 infectious effect Effects 0.000 claims description 16
- 238000010790 dilution Methods 0.000 claims description 15
- 239000012895 dilution Substances 0.000 claims description 15
- 230000035931 haemagglutination Effects 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 238000006386 neutralization reaction Methods 0.000 claims description 11
- 241000712461 unidentified influenza virus Species 0.000 claims description 11
- 238000012512 characterization method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 9
- 239000000185 hemagglutinin Substances 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- 238000005215 recombination Methods 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000036438 mutation frequency Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000000670 limiting effect Effects 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 206010022000 influenza Diseases 0.000 description 41
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 230000036039 immunity Effects 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 101710154606 Hemagglutinin Proteins 0.000 description 7
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 7
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 7
- 101710176177 Protein A56 Proteins 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 210000004201 immune sera Anatomy 0.000 description 7
- 229940042743 immune sera Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000282339 Mustela Species 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7226337A FR2201876B1 (OSRAM) | 1972-07-21 | 1972-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2337134A1 true DE2337134A1 (de) | 1974-02-14 |
Family
ID=9102179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732337134 Withdrawn DE2337134A1 (de) | 1972-07-21 | 1973-07-20 | Verfahren zur herstellung eines grippeimpfstoffes |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS4980229A (OSRAM) |
| BE (1) | BE802649A (OSRAM) |
| CA (1) | CA1030872A (OSRAM) |
| CH (1) | CH613229A5 (OSRAM) |
| DD (1) | DD107719A5 (OSRAM) |
| DE (1) | DE2337134A1 (OSRAM) |
| ES (1) | ES417157A1 (OSRAM) |
| FR (1) | FR2201876B1 (OSRAM) |
| GB (1) | GB1443958A (OSRAM) |
| IL (1) | IL42749A0 (OSRAM) |
| NL (1) | NL7310127A (OSRAM) |
| ZA (1) | ZA734817B (OSRAM) |
-
1972
- 1972-07-21 FR FR7226337A patent/FR2201876B1/fr not_active Expired
-
1973
- 1973-07-16 ZA ZA734817A patent/ZA734817B/xx unknown
- 1973-07-16 IL IL42749A patent/IL42749A0/xx unknown
- 1973-07-20 CH CH1066973A patent/CH613229A5/xx not_active IP Right Cessation
- 1973-07-20 NL NL7310127A patent/NL7310127A/xx not_active Application Discontinuation
- 1973-07-20 CA CA177,015A patent/CA1030872A/en not_active Expired
- 1973-07-20 DD DD172401A patent/DD107719A5/xx unknown
- 1973-07-20 DE DE19732337134 patent/DE2337134A1/de not_active Withdrawn
- 1973-07-20 JP JP48082428A patent/JPS4980229A/ja active Pending
- 1973-07-20 BE BE133744A patent/BE802649A/xx unknown
- 1973-07-20 GB GB3461773A patent/GB1443958A/en not_active Expired
- 1973-07-21 ES ES417157A patent/ES417157A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL42749A0 (en) | 1973-10-25 |
| GB1443958A (en) | 1976-07-28 |
| DD107719A5 (OSRAM) | 1974-08-12 |
| JPS4980229A (OSRAM) | 1974-08-02 |
| CH613229A5 (en) | 1979-09-14 |
| NL7310127A (OSRAM) | 1974-01-23 |
| FR2201876A1 (OSRAM) | 1974-05-03 |
| FR2201876B1 (OSRAM) | 1975-11-28 |
| ES417157A1 (es) | 1976-03-01 |
| CA1030872A (en) | 1978-05-09 |
| ZA734817B (en) | 1974-06-26 |
| BE802649A (fr) | 1974-01-21 |
| AU5817173A (en) | 1975-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
| DE3889138T2 (de) | Influenza-Impfstoff. | |
| DE2708668A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE3886999T3 (de) | Newcastle-krankheitsvirus-Impfstoff und Methode für seine Verwendung. | |
| DE69836976T2 (de) | Neospora impstoff | |
| DE2423129A1 (de) | Verfahren zur herstellung temperaturempfindlicher, nicht pathogener mutantenstaemme von rinder-adeno-virusstaemmen und diese virusstaemme enthaltende lebendvakzine | |
| DE2616407A1 (de) | Tollwut-vaccine und verfahren zu ihrer herstellung | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE3034238A1 (de) | Impfstoff zur bekaempfung der newcastle-krankheit und verfahren zur herstellung derselben | |
| DE3783409T2 (de) | Verfahren zur besserung der qualitaet von tieren. | |
| DE69615772T2 (de) | Milder Newcastle-Krankheitsimpfstoff | |
| DE2456636A1 (de) | Influenza-vakzine und verfahren zu ihrer herstellung | |
| DE2415353C2 (OSRAM) | ||
| Findlay | Immunological and serological studies on the viruses of fowl-pox and vaccinia | |
| DE2632255A1 (de) | Neues rabiesvirusvakzin und verfahren zu dessen herstellung | |
| DE2739439C2 (OSRAM) | ||
| DE2337134A1 (de) | Verfahren zur herstellung eines grippeimpfstoffes | |
| DE3878982T2 (de) | Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus. | |
| DE1617756A1 (de) | Verfahren zur Herstellung einer neuen Antivirusvaccine | |
| DE68927380T2 (de) | Impfstoff | |
| Aitken et al. | Observations on the serological and dermal responses of turkeys to a single subcutaneous inoculation of inactivated Newcastle disease vaccine in mineral oil adjuvant | |
| EP0210552B1 (de) | Tollwut-Lebendimpfstoff | |
| DE2045160A1 (de) | Verfahren zur Herstellung einer Lebendvaccine gegen die infektiöse Bursitis der Huhner | |
| DE69208854T2 (de) | Impfstoff-Zubereitung zur Vorbeugung gegen bei Tieren durch Chlamydia psitacci verursachte Fehlgeburt | |
| DE2728806A1 (de) | Auf oralem wege einzunehmender antiparasitaerer impfstoff, verfahren zu dessen herstellung und anwendungsmethode des impfstoffs bei saeugetieren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |